Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.
2.

p53 Mediates Failure of Human Definitive Hematopoiesis in Dyskeratosis Congenita.

Fok WC, Niero ELO, Dege C, Brenner KA, Sturgeon CM, Batista LFZ.

Stem Cell Reports. 2017 Aug 8;9(2):409-418. doi: 10.1016/j.stemcr.2017.06.015. Epub 2017 Jul 27.

3.

Human definitive hematopoietic specification from pluripotent stem cells is regulated by mesodermal expression of CDX4.

Creamer JP, Dege C, Ren Q, Ho JTK, Valentine MC, Druley TE, Sturgeon CM.

Blood. 2017 Jun 1;129(22):2988-2992. doi: 10.1182/blood-2016-11-749382. Epub 2017 Apr 13.

4.

A view of human haematopoietic development from the Petri dish.

Ditadi A, Sturgeon CM, Keller G.

Nat Rev Mol Cell Biol. 2017 Jan;18(1):56-67. doi: 10.1038/nrm.2016.127. Epub 2016 Nov 23. Review.

PMID:
27876786
5.

Perspective and priorities for improvement of parathyroid hormone (PTH) measurement - A view from the IFCC Working Group for PTH.

Sturgeon CM, Sprague S, Almond A, Cavalier E, Fraser WD, Algeciras-Schimnich A, Singh R, Souberbielle JC, Vesper HW; IFCC Working Group for PTH.

Clin Chim Acta. 2017 Apr;467:42-47. doi: 10.1016/j.cca.2016.10.016. Epub 2016 Oct 13. Review.

6.

Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.

Sölétormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, Bast RC Jr, Gaarenstroom KN, Sturgeon CM, Bonfrer JM, Petersen PH, Troonen H, CarloTorre G, Kanty Kulpa J, Tuxen MK, Molina R.

Int J Gynecol Cancer. 2016 Jan;26(1):43-51. doi: 10.1097/IGC.0000000000000586.

7.

Directed differentiation of definitive hemogenic endothelium and hematopoietic progenitors from human pluripotent stem cells.

Ditadi A, Sturgeon CM.

Methods. 2016 May 15;101:65-72. doi: 10.1016/j.ymeth.2015.10.001. Epub 2015 Oct 9.

PMID:
26439174
8.

Human definitive haemogenic endothelium and arterial vascular endothelium represent distinct lineages.

Ditadi A, Sturgeon CM, Tober J, Awong G, Kennedy M, Yzaguirre AD, Azzola L, Ng ES, Stanley EG, French DL, Cheng X, Gadue P, Speck NA, Elefanty AG, Keller G.

Nat Cell Biol. 2015 May;17(5):580-91. doi: 10.1038/ncb3161. Epub 2015 Apr 27.

9.

Validation of new cancer biomarkers: a position statement from the European group on tumor markers.

Duffy MJ, Sturgeon CM, Sölétormos G, Barak V, Molina R, Hayes DF, Diamandis EP, Bossuyt PM.

Clin Chem. 2015 Jun;61(6):809-20. doi: 10.1373/clinchem.2015.239863. Epub 2015 Apr 16. Review.

10.

Wnt signaling controls the specification of definitive and primitive hematopoiesis from human pluripotent stem cells.

Sturgeon CM, Ditadi A, Awong G, Kennedy M, Keller G.

Nat Biotechnol. 2014 Jun;32(6):554-61. doi: 10.1038/nbt.2915. Epub 2014 May 18.

11.

The harmonisation of growth hormone measurements: taking the next steps.

Wieringa GE, Sturgeon CM, Trainer PJ.

Clin Chim Acta. 2014 May 15;432:68-71. doi: 10.1016/j.cca.2014.01.014. Epub 2014 Feb 6. Review.

PMID:
24509000
12.

Common decision limits --The need for harmonised immunoassays.

Sturgeon CM.

Clin Chim Acta. 2014 May 15;432:122-6. doi: 10.1016/j.cca.2013.11.023. Epub 2013 Nov 27. Review.

PMID:
24291707
13.

External quality assessment of hormone determinations.

Sturgeon CM.

Best Pract Res Clin Endocrinol Metab. 2013 Dec;27(6):803-22. doi: 10.1016/j.beem.2013.08.009. Epub 2013 Sep 5. Review.

14.

Sampling and storage conditions influencing the measurement of parathyroid hormone in blood samples: a systematic review.

Hanon EA, Sturgeon CM, Lamb EJ.

Clin Chem Lab Med. 2013 Oct;51(10):1925-41. doi: 10.1515/cclm-2013-0315. Review.

PMID:
24072573
15.

[The ways of harmonization of clinical laboratory measurement techniques].

Miller WG, Myers GL, Gantzer ML, Kahn SE, Schönbrunner ER, Thienpont LM, Bunk DM, Christenson RH, Eckfeldt JH, Stanley GL, Nubling CM, Sturgeon CM.

Klin Lab Diagn. 2013 Feb;(2):54-61. Russian.

PMID:
23808013
16.

Defining the path to hematopoietic stem cells.

Sturgeon CM, Ditadi A, Clarke RL, Keller G.

Nat Biotechnol. 2013 May;31(5):416-8. doi: 10.1038/nbt.2571. No abstract available.

PMID:
23657396
17.

T lymphocyte potential marks the emergence of definitive hematopoietic progenitors in human pluripotent stem cell differentiation cultures.

Kennedy M, Awong G, Sturgeon CM, Ditadi A, LaMotte-Mohs R, Zúñiga-Pflücker JC, Keller G.

Cell Rep. 2012 Dec 27;2(6):1722-35. doi: 10.1016/j.celrep.2012.11.003. Epub 2012 Dec 7.

18.

Design of tumor biomarker-monitoring trials: a proposal by the European Group on Tumor Markers.

Sölétormos G, Duffy MJ, Hayes DF, Sturgeon CM, Barak V, Bossuyt PM, Diamandis EP, Gion M, Hyltoft-Petersen P, Lamerz RM, Nielsen DL, Sibley P, Tholander B, Tuxen MK, Bonfrer JM.

Clin Chem. 2013 Jan;59(1):52-9. doi: 10.1373/clinchem.2011.180778. Epub 2012 Oct 3.

19.

Primitive erythropoiesis is regulated by miR-126 via nonhematopoietic Vcam-1+ cells.

Sturgeon CM, Chicha L, Ditadi A, Zhou Q, McGrath KE, Palis J, Hammond SM, Wang S, Olson EN, Keller G.

Dev Cell. 2012 Jul 17;23(1):45-57. doi: 10.1016/j.devcel.2012.05.021. Epub 2012 Jun 28.

20.

Variation in parathyroid hormone immunoassay results--a critical governance issue in the management of chronic kidney disease.

Sturgeon CM, Sprague SM, Metcalfe W.

Nephrol Dial Transplant. 2011 Nov;26(11):3440-5. doi: 10.1093/ndt/gfr614. Review.

21.

Analytical error and interference in immunoassay: minimizing risk.

Sturgeon CM, Viljoen A.

Ann Clin Biochem. 2011 Sep;48(Pt 5):418-32. doi: 10.1258/acb.2011.011073. Epub 2011 Jul 12. Review.

PMID:
21750113
22.

The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: the pivotal role of the clinical laboratory.

Sturgeon CM, Duffy MJ, Walker G.

Ann Clin Biochem. 2011 Jul;48(Pt 4):295-9. doi: 10.1258/acb.2011.011117.

PMID:
21746796
23.

Roadmap for harmonization of clinical laboratory measurement procedures.

Greg Miller W, Myers GL, Lou Gantzer M, Kahn SE, Schönbrunner ER, Thienpont LM, Bunk DM, Christenson RH, Eckfeldt JH, Lo SF, Nübling CM, Sturgeon CM.

Clin Chem. 2011 Aug;57(8):1108-17. doi: 10.1373/clinchem.2011.164012. Epub 2011 Jun 15.

24.

Interaction of gonadal status with systemic inflammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer.

Skipworth RJ, Moses AG, Sangster K, Sturgeon CM, Voss AC, Fallon MT, Anderson RA, Ross JA, Fearon KC.

Support Care Cancer. 2011 Mar;19(3):391-401. doi: 10.1007/s00520-010-0832-y. Epub 2010 Mar 12.

PMID:
20221887
25.

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers.

Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, Bonfrer J, Ecke TH, Grossman HB, Hayes P, Hoffmann RT, Lerner SP, Löhe F, Louhimo J, Sawczuk I, Taketa K, Diamandis EP; National Academy of Clinical Biochemistry.

Clin Chem. 2010 Jun;56(6):e1-48. doi: 10.1373/clinchem.2009.133124. Epub 2010 Mar 5.

26.

Mass spectrometric detection of candidate protein biomarkers of cancer cachexia in human urine.

Skipworth RJ, Stewart GD, Bhana M, Christie J, Sturgeon CM, Guttridge DC, Cronshaw AD, Fearon KC, Ross JA.

Int J Oncol. 2010 Apr;36(4):973-82.

PMID:
20198343
27.

Serum tumour markers: how to order and interpret them.

Sturgeon CM, Lai LC, Duffy MJ.

BMJ. 2009 Sep 22;339:b3527. doi: 10.1136/bmj.b3527. Review. No abstract available. Erratum in: BMJ. 2009;339. doi: 10.1136/bmj.b4079.

PMID:
19773328
28.

Differences in recognition of the 1st WHO international reference reagents for hCG-related isoforms by diagnostic immunoassays for human chorionic gonadotropin.

Sturgeon CM, Berger P, Bidart JM, Birken S, Burns C, Norman RJ, Stenman UH; IFCC Working Group on hCG.

Clin Chem. 2009 Aug;55(8):1484-91. doi: 10.1373/clinchem.2009.124578. Epub 2009 Jun 18.

29.

National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.

Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC Jr, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih IeM, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP; National Academy of Clinical Biochemistry.

Clin Chem. 2008 Dec;54(12):e11-79. doi: 10.1373/clinchem.2008.105601.

30.

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for the Use of Tumor Markers.

Diamandis EP, Hoffman BR, Sturgeon CM.

Clin Chem. 2008 Nov;54(11):1935-9. doi: 10.1373/clinchem.2008.105494. Epub 2008 Sep 18. No abstract available.

31.

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements.

Sturgeon CM, Hoffman BR, Chan DW, Ch'ng SL, Hammond E, Hayes DF, Liotta LA, Petricoin EF, Schmitt M, Semmes OJ, Söletormos G, van der Merwe E, Diamandis EP; National Academy of Clinical Biochemistry.

Clin Chem. 2008 Aug;54(8):e1-e10. doi: 10.1373/clinchem.2007.094144. Epub 2008 Jul 7.

32.

Abrogation of ionizing radiation-induced G2 checkpoint and inhibition of nuclear export by Cryptocarya pyrones.

Sturgeon CM, Cinel B, Díaz-Marrero AR, McHardy LM, Ngo M, Andersen RJ, Roberge M.

Cancer Chemother Pharmacol. 2008 Mar;61(3):407-13. Epub 2007 Apr 18.

PMID:
17440726
33.

Nigricanosides A and B, antimitotic glycolipids isolated from the green alga Avrainvillea nigricans collected in Dominica.

Williams DE, Sturgeon CM, Roberge M, Andersen RJ.

J Am Chem Soc. 2007 May 9;129(18):5822-3. Epub 2007 Apr 18. No abstract available.

PMID:
17439220
34.

Improving the comparability of immunoassays for prostate-specific antigen (PSA): progress and problems.

Sturgeon CM, Ellis AR.

Clin Chim Acta. 2007 May;381(1):85-92. Epub 2007 Feb 20. Review.

PMID:
17408608
35.

G2 checkpoint kinase inhibitors exert their radiosensitizing effects prior to the G2/M transition.

Sturgeon CM, Roberge M.

Cell Cycle. 2007 Mar 1;6(5):572-5. Epub 2007 Mar 31.

PMID:
17351346
36.

Inhibition of the G2 DNA damage checkpoint by oliveroline isolated from Duguetia odorata.

Brastianos HC, Sturgeon CM, Roberge M, Andersen RJ.

J Nat Prod. 2007 Feb;70(2):287-8.

PMID:
17315964
37.

Standardization of FSH, LH and hCG--current position and future prospects.

Sturgeon CM, Ellis AR.

Mol Cell Endocrinol. 2007 Jan 2;260-262:301-9. Epub 2006 Nov 16. Review.

PMID:
17113221
38.

Yeast as a tool to uncover the cellular targets of drugs.

Sturgeon CM, Kemmer D, Anderson HJ, Roberge M.

Biotechnol J. 2006 Mar;1(3):289-98. Review.

PMID:
16897709
39.

Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage.

Sturgeon CM, Knight ZA, Shokat KM, Roberge M.

Mol Cancer Ther. 2006 Apr;5(4):885-92.

40.

Modulation of the G2 cell cycle checkpoint by sesquiterpene lactones psilostachyins A and C isolated from the common ragweed Ambrosia artemisiifolia.

Sturgeon CM, Craig K, Brown C, Rundle NT, Andersen RJ, Roberge M.

Planta Med. 2005 Oct;71(10):938-43.

PMID:
16254826
41.

Freeze-induced expression of a novel gene, fr47, in the liver of the freeze-tolerant wood frog, Rana sylvatica.

McNally JD, Sturgeon CM, Storey KB.

Biochim Biophys Acta. 2003 Jan 27;1625(2):183-91.

PMID:
12531477
42.

Identification and characterization of a novel freezing inducible gene, li16, in the wood frog Rana sylvatica.

McNally JD, Wu SB, Sturgeon CM, Storey KB.

FASEB J. 2002 Jun;16(8):902-4. Epub 2002 Apr 23.

PMID:
12039874
43.

Tumor markers in the laboratory: closing the guideline-practice gap.

Sturgeon CM.

Clin Biochem. 2001 Jul;34(5):353-9.

PMID:
11522270
44.

Acute-phase protein response, survival and tumour recurrence in patients with colorectal cancer.

Wigmore SJ, McMahon AJ, Sturgeon CM, Fearon KC.

Br J Surg. 2001 Feb;88(2):255-60.

PMID:
11167877
45.

Analysis of hCG: clinical applications and assay requirements.

Sturgeon CM, McAllister EJ.

Ann Clin Biochem. 1998 Jul;35 ( Pt 4):460-91. Review.

PMID:
9681050
46.
47.

Serological markers for metastatic breast cancer.

Ng JS, Sturgeon CM, Seth J, Paterson GM, Roulston JE, Leonard RC.

Dis Markers. 1993 Dec;11(5-6):217-23.

PMID:
8082311
48.

Effect of bowel cleansing and colonoscopy on serum CEA levels.

Turner J, Sturgeon CM.

J R Coll Surg Edinb. 1993 Apr;38(2):89-91.

PMID:
8478841
49.

Validation of target values in external quality assessment schemes for peptide hormones and tumour markers.

Seth J, Sturgeon CM, Ellis AR, al Sadie R.

Scand J Clin Lab Invest Suppl. 1993;212:28-30.

PMID:
8465148
50.

External quality assessment of immunoassays of peptide hormones and tumour markers: principles and practice.

Seth J, Sturgeon CM, al-Sadie R, Hanning I, Ellis AR.

Ann Ist Super Sanita. 1991;27(3):443-52. Review.

PMID:
1809063

Supplemental Content

Loading ...
Support Center